I added TSRX at $5.18.
Trius Therapeutics (TSRX) is developing antibiotics. Its lead candidate is Tedizolid Phosphate which is being developed for use in acute bacterial skin and skin structure infections (ABSSSIs).
Tedizolid is a second-generation oxazolidinone. The first-generation oxazolidinone, linezolid, is marketed by Pfizer and has estimated revenues of $1.3B per year. Tedizolid has some potentially beneficial characteristics including: once-daily dosing, a shorter course of therapy, and better safety profile.
TSRX published the results of its first phase-3 Tedizolid trial (ESTABLISH-1) in December 2011. The results showed the drug meeting the primary end-point of establishing non-inferiority to linezolid when assessed by early clinical response. In addition, the drug met all of the secondary efficacy outcomes.
Trius commenced its second phase-3 trial in September 2012. The trial concluded at the end of the year and preliminary results are expected in March. Assuming a successful trial an NDA submission should follow later in the year.
Within the last year the company has traded as high as $6.40. It closed today at $5.20. It is well funded following a secondary offering in January, which precipitated a drop from $5.42 to $4.90. It seems that there is room for some appreciation ahead of the final pivotal trial for an antibiotic with significant market potential.